|Articles|November 1, 2022

Supplements and Featured Publications

  • Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update
  • Volume 28
  • Issue 12

What are the current challenges to wider biosimilar use in the United States?

Plain Language Summary

Plain Language Summary

Click the image to open in a new window.

Articles in this issue

over 3 years ago

Participating Faculty: Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

over 3 years ago

Introduction to Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update

over 3 years ago

Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence

over 3 years ago

Biosimilar medicines: what are they and how are they used?

over 3 years ago

Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

over 3 years ago

What do patients and health care providers still need to know about biosimilar medicines?

over 3 years ago

eAppendix: Provider and Patient Knowledge Gaps on Biosimilars: Insights From Surveys

over 3 years ago

Biosimilars for Immune-Mediated Inflammatory Diseases – A Managed Care Perspective

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs
Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

View more
Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care
AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

View more
Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text